ISIS up +0.40% percent Today $ISIS High is at 50.1
Post# of 115
Posted On: 11/19/2014 2:05:56 PM
ISIS up +0.40% percent Today $ISIS High is at 50.10 and the Low 49.08 with current volume of 187,107.
Recent News posted below.
Isis Pharmaceuticals ISIS other info.
http://investorshangout.com/Isis-Pharmaceuticals-ISIS-54504/
ISIS Isis Pharmaceuticals Recent Headline News
Regulus To See Further Declines
Richard Pearson - Seeking Alpha - Wed Nov 19, 9:30AM CST
On October 22nd, Regulus Therapeutics (NASDAQ: RGLS ) released its " proof of concept " data for its Hep C drug RG-101. The stock price quickly soared from its prior level of $6-7 to as high as $25 (intra day) as enthusiasm for the drug ran...
ISIS: 50.35 (+0.64), ALNY: 90.70 (+0.75), ACHN: 12.94 (-0.37), RGLS: 16.63 (-1.49)
Global Antisense and RNAi Therapeutics Market 2015-2019
M2 - Wed Nov 19, 6:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/6m9z2s/global_antisense) has announced the addition of the "Global Antisense and RNAi Therapeutics Market 2015-2019" report to their offering. The analysts forecast the Global Antisense and RNAi Therapeutics market to grow at a CAGR of 26.79% over the period 2014-2019. RNAi and antisense are two predominant technologies used by pharmaceutical companies, research institutes, and others for various applications such as research, diagnostics, and therapeutics. RNAi therapeutics have a large scope in the treatment of diseases such as cancer and neurodegenerative disorders. There are two types of RNA molecules used in the RNAi technology: miRNA and siRNA. One of the main trends upcoming in this market is the increased strategic collaborations and licensing activities. Many big pharmaceutical and biotechnology companies are collaborating with other companies to develop and commercialize antisense and RNAi drugs in the market. According to the report, one of the major drivers in this market is the advances in technology. Demand for gene silencing by antisense and RNAi is gaining popularity because of its high efficiency. Advances in technology in antisense and RNAi technology help to design and develop antisense and RNAi therapeutics that can suppress the expression of the targeted genes with high specificity. Further, the report states that one of the major challenges in this market is the toxicity of antisense and RNAi-based drugs. Therapeutic antisense oligonucleotides and RNAi drugs have adverse side effects on the body especially on the liver. Key Vendors - Alnylam Pharmaceuticals - Isis Pharmaceuticals - Sanofi - Tekmira Pharmaceuticals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Technology - Market Segmentation by Therapeutics Area - Geographical Segmentation - Buying Criteria - Pipeline Snapshot - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/6m..._antisense
ISIS: 50.35 (+0.64), TKMR: 16.41 (+0.04)
Genzyme and Isis Pharma announce presentation on cardiac benefits of Kynamro
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 3:37PM CST
ISIS: 50.39 (+0.68), SNY: 48.33 (-0.03)
Genzyme and Isis Present KYNAMRO(R) Clinical Data at the American Heart Association
Business Wire - Tue Nov 18, 2:45PM CST
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that new two-year data from a phase 3 long-term extension study of KYNAMRO(R) (mipomersen sodium) injection was presented at a scientific session at the annual American Heart Association meeting in Chicago, IL. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events (MACE) compared to two years prior to therapy.
ISIS: 50.39 (+0.68), SNY: 48.33 (-0.03)
Global miRNA Research and Diagnostics Markets Report 2014
M2 - Tue Nov 18, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjgcv3/mirna_research) has announced the addition of the "miRNA Research and Diagnostics Markets" report to their offering. This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that donot produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, alarge number of companies, both small biotechs and big pharmaceutical companiesare committed to miRNA diagnostics. As part of its coverage of this topic, this report includes the following: - Overview of miRNAs - Positive Factors for miRNA Diagnostic Technologies - Negative Factors - miRNAs and Neurological Disorders - miRNA and Metastatic Brain Lesions - Prostate Cancer Screening and miRNAs - miRNAs and Resistance to Anti-Cancer Drugs - Theoretical Limitations - Discussion of Patent Issues - Interviews with Industry Experts - Market Estimate As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail: - Agilent Technologies - AMSBIO - Applied Biosystems - DiamiR, LLC - Dicerna - Eisai Biomarkers and Personalized Medicine - Diagnostics - Genomic Health Inc. - Gensignia - GlaxoSmithKline Discovery and Molecular Toxicology - Groove Biopharma (formerly Mirina) - Hologic-Gen Probe Inc. - Illumina, Inc. - Isis Pharmaceuticals - Mello Biotechnology Inc. - Microlin Bio - MiRagen Therapeutics - MiRNA Therapeutics - Novartis - Pacific Edge Biotechnology - Prolias Technologies - Regulus Therapeutics - Rosetta Genomics - Santaris Pharma A/S - Sirnaomics, Inc. - Somagenics - Diagnostics: Small RNA Assays and Biomarker Validation - Tekmira Pharmaceuticals Corporation - Thermadiag - Thermo Fisher Scientific, Inc. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Current State of the Art 4. Companies Developing microRNA Diagnostic Technologies 5. Market Estimates and Forecasts 6. Interviews with Industry Experts: Biomarkers 7. The Future of miRNA-Based Diagnostics For more information visit http://www.researchandmarkets.com/research/fj...a_research
ISIS: 50.39 (+0.68), A: 40.90 (+0.10), TKMR: 16.41 (+0.04), ILMN: 190.42 (+0.57), RGLS: 16.63 (-1.49), GSK: 46.38 (+0.10), HOLX: 26.39 (-0.25), GHDX: 32.50 (-0.04), NVS: 95.75 (+0.17)
Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting
PR Newswire - Tue Nov 18, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Monday, December 8, 2014 at 9:00 a.m. Eastern Time to discuss the ISIS-FXIRx data presented at the 56th American Society of Hematology Annual Meeting and Exposition.
ISIS: 50.39 (+0.68)
Post Earnings Update: Isis Pharmaceuticals Has Climbed 9.8% Higher in Past Week (ISIS)
Comtex SmarTrend(R) - Mon Nov 17, 3:34PM CST
When Isis Pharmaceuticals (NASDAQ:ISIS) reported earnings a week ago on November 7th, 2014, analysts, on average, expected the company to report a loss of $0.20 on sales of $44.2 million. Isis Pharmaceuticals actually reported a loss of $0.23 per share on sales of $44.1 million, missing EPS estimates by $0.04 and matching revenue estimates. Shares of Isis Pharmaceuticals have climbed from $44.59 to $48.98, representing a gain of 9.8% since the company reported earnings 10 days ago.
ISIS: 50.39 (+0.68)
Cure SMA Presents Isis Pharmaceuticals with SMA Breakthrough Award
PR Newswire - Mon Nov 17, 11:04AM CST
On November 15, Isis Pharmaceuticals (NASDAQ: ISIS) was presented with the 2014 SMA Breakthrough Award as part of the Cure SMA Gala of Hope in Seal Beach, CA. The award was accepted by Stanley T Crooke, Ph.D., M.D., who is the founder, chairman, and chief executive officer of Isis Pharmaceuticals.
ISIS: 50.39 (+0.68)
Isis Pharmaceuticals Up 49.0% Since SmarTrend Uptrend Call (ISIS)
Comtex SmarTrend(R) - Mon Nov 17, 9:26AM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 3 months, Isis Pharmaceuticals has returned 48.98% as of today's recent price of $49.35.
ISIS: 50.39 (+0.68)
Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 303.63 (-1.93), ISIS: 50.39 (+0.68), AZN: 75.48 (+1.50), SNY: 48.35 (-0.01)
Isis Pharmaceuticals to Present at Upcoming Investor Conferences
PR Newswire - Fri Nov 14, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at:
ISIS: 50.39 (+0.68)
Cramer's Lightning Round - VeriFone Is Going To Have A Big Year (11/12/14)
SA Editor Miriam Metzinger - Seeking Alpha - Thu Nov 13, 8:05AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday November 12. Bullish Calls: VeriFone (NYSE: PAY ): "I like it. It is integral to Apple Pay. It is going to have a big year." ...
BTU: 10.72 (-0.54), ISIS: 50.39 (+0.68), FRT: 131.53 (-0.60), PAY: 36.74 (-0.25)
'Mad Money' Lightning Round: VeriFone Is Integral to ApplePlay
at The Street - Thu Nov 13, 5:00AM CST
Cramer says Hertz is very cheap but wants to see how their accounting problems play out.
DDR: 17.87 (-0.20), BTU: 10.72 (-0.54), HTZ: 22.18 (-0.50), ISIS: 50.39 (+0.68), ISBC: 10.74 (-0.03), FRT: 131.53 (-0.60), BAC: 17.04 (-0.10), PAY: 36.74 (-0.25)
AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods
PR Newswire - Thu Nov 13, 2:01AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively. The agreement builds on an existing collaboration between AstraZeneca and Isis Pharmaceuticals, a leader in the field of antisense, and supports AstraZeneca's research and development capabilities in the area of antisense oligonucleotide-based therapeutics and RNA biology. Initial project areas will be oncology and cardiovascular and metabolic diseases (CVMD).
ISIS: 50.39 (+0.68)
Jim Cramer's 'Mad Money' Recap: Pining for Quiet Stock That Climbs
at The Street - Wed Nov 12, 7:57PM CST
While the bulls and bears battle it out over high-flying stocks like Alibaba and Twitter, Cramer said he'd rather just own Apple because it doesn't make waves, it makes money.
HTZ: 22.18 (-0.50), PNRA: 168.65 (+0.70), FB: 73.84 (-0.50), TCS: 22.63 (-0.59), BAC: 17.04 (-0.10), FRT: 131.53 (-0.60), YHOO: 51.17 (-0.58), DDR: 17.87 (-0.20), BTU: 10.72 (-0.54), SAVE: 76.09 (-0.24), ISIS: 50.39 (+0.68), CMG: 658.01 (-0.08), AAL: 44.59 (-0.46), ISBC: 10.74 (-0.03), PAY: 36.74 (-0.25), TWTR: 39.62 (-0.99), DOW: 51.48 (-0.59), BABA: 109.77 (-1.04)
Critical Alerts For Twitter, Isis Pharmaceuticals, TrueCar and Myriad Genetics Released By InvestorsObserver
PR Newswire - Wed Nov 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for TWTR, ISIS, TRUE and MYGN.
MYGN: 32.30 (-0.56), ISIS: 50.39 (+0.68), TRUE: 17.74 (+0.32), TWTR: 39.62 (-0.99)
Isis Pharmaceuticals Prices Offering of $425 Million of 1.00% Convertible Senior Notes
PR Newswire - Wed Nov 12, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the pricing of its offering of $425.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes"
in a private placement. Isis also granted the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $75.0 million aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. The sale of the Convertible Notes is expected to close on November 17, 2014, subject to customary closing conditions.
ISIS: 50.39 (+0.68)
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 12, 4:20AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 11. CEO Interview: Bill Tauscher, Blackhawk (NASDAQ: HAWK ). Other stocks mentioned: Safeway (NYSE: SWY ) Blackhawk ( HAWK ) is a leading global...
WFM: 47.85 (-0.04), DHI: 24.67 (+0.04), AMZN: 326.78 (+1.85), TSLA: 248.35 (-9.35), KR: 58.47 (-0.05), SWY: 34.85 (+0.07), CLX: 100.52 (-0.25), XOM: 95.41 (+0.54), FCAU: 12.25 (-0.56), INO: 9.50 (-0.36), WHR: 179.27 (+2.05), T: 35.35 (-0.37), ISIS: 50.39 (+0.68), VALE: 8.56 (+0.03), EOG: 98.46 (+0.79), HAWK: 35.32 (-1.02), SHW: 240.18 (-1.14), VZ: 50.48 (-0.74), TOL: 33.96 (+0.07), REGN: 416.07 (+2.85), KELYA: 15.51 (-0.08), BABA: 109.82 (-0.99)
Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names
at The Street - Tue Nov 11, 7:59PM CST
Cramer says record-low interest rates seem to have finally paid off for the home builders. That means good things for the folks who make interior items, too.
DHI: 24.67 (+0.04), TSLA: 248.35 (-9.35), AMZN: 326.78 (+1.85), CY: 10.47 (+0.12), XOM: 95.41 (+0.54), KEX: 101.47 (+1.22), LRN: 12.14 (-0.29), BWLD: 162.49 (+1.63), ADBE: 70.83 (unch), GTLS: 42.24 (-0.87), TWX: 81.18 (+0.68), WHR: 179.27 (+2.05), T: 35.35 (-0.37), LYB: 88.88 (-0.16), ISIS: 50.39 (+0.68), CMG: 658.01 (-0.08), EOG: 98.46 (+0.79), HAWK: 35.32 (-1.02), SHW: 240.18 (-1.14), VZ: 50.48 (-0.74), DOW: 51.48 (-0.59), REGN: 416.07 (+2.85), KELYA: 15.51 (-0.08), CBS: 52.71 (+0.17)
Isis Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 8.81%
Comtex SmarTrend(R) - Tue Nov 11, 3:42PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $48.10 to a high of $52.24. Yesterday, the shares gained 8.8%, which took the trading range above the 3-day high of $47.25 on volume of 10.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ISIS: 50.39 (+0.68)
Recent News posted below.
Isis Pharmaceuticals ISIS other info.
http://investorshangout.com/Isis-Pharmaceuticals-ISIS-54504/
ISIS Isis Pharmaceuticals Recent Headline News
Regulus To See Further Declines
Richard Pearson - Seeking Alpha - Wed Nov 19, 9:30AM CST
On October 22nd, Regulus Therapeutics (NASDAQ: RGLS ) released its " proof of concept " data for its Hep C drug RG-101. The stock price quickly soared from its prior level of $6-7 to as high as $25 (intra day) as enthusiasm for the drug ran...
ISIS: 50.35 (+0.64), ALNY: 90.70 (+0.75), ACHN: 12.94 (-0.37), RGLS: 16.63 (-1.49)
Global Antisense and RNAi Therapeutics Market 2015-2019
M2 - Wed Nov 19, 6:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/6m9z2s/global_antisense) has announced the addition of the "Global Antisense and RNAi Therapeutics Market 2015-2019" report to their offering. The analysts forecast the Global Antisense and RNAi Therapeutics market to grow at a CAGR of 26.79% over the period 2014-2019. RNAi and antisense are two predominant technologies used by pharmaceutical companies, research institutes, and others for various applications such as research, diagnostics, and therapeutics. RNAi therapeutics have a large scope in the treatment of diseases such as cancer and neurodegenerative disorders. There are two types of RNA molecules used in the RNAi technology: miRNA and siRNA. One of the main trends upcoming in this market is the increased strategic collaborations and licensing activities. Many big pharmaceutical and biotechnology companies are collaborating with other companies to develop and commercialize antisense and RNAi drugs in the market. According to the report, one of the major drivers in this market is the advances in technology. Demand for gene silencing by antisense and RNAi is gaining popularity because of its high efficiency. Advances in technology in antisense and RNAi technology help to design and develop antisense and RNAi therapeutics that can suppress the expression of the targeted genes with high specificity. Further, the report states that one of the major challenges in this market is the toxicity of antisense and RNAi-based drugs. Therapeutic antisense oligonucleotides and RNAi drugs have adverse side effects on the body especially on the liver. Key Vendors - Alnylam Pharmaceuticals - Isis Pharmaceuticals - Sanofi - Tekmira Pharmaceuticals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Technology - Market Segmentation by Therapeutics Area - Geographical Segmentation - Buying Criteria - Pipeline Snapshot - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/6m..._antisense
ISIS: 50.35 (+0.64), TKMR: 16.41 (+0.04)
Genzyme and Isis Pharma announce presentation on cardiac benefits of Kynamro
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 3:37PM CST
ISIS: 50.39 (+0.68), SNY: 48.33 (-0.03)
Genzyme and Isis Present KYNAMRO(R) Clinical Data at the American Heart Association
Business Wire - Tue Nov 18, 2:45PM CST
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that new two-year data from a phase 3 long-term extension study of KYNAMRO(R) (mipomersen sodium) injection was presented at a scientific session at the annual American Heart Association meeting in Chicago, IL. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events (MACE) compared to two years prior to therapy.
ISIS: 50.39 (+0.68), SNY: 48.33 (-0.03)
Global miRNA Research and Diagnostics Markets Report 2014
M2 - Tue Nov 18, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjgcv3/mirna_research) has announced the addition of the "miRNA Research and Diagnostics Markets" report to their offering. This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that donot produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, alarge number of companies, both small biotechs and big pharmaceutical companiesare committed to miRNA diagnostics. As part of its coverage of this topic, this report includes the following: - Overview of miRNAs - Positive Factors for miRNA Diagnostic Technologies - Negative Factors - miRNAs and Neurological Disorders - miRNA and Metastatic Brain Lesions - Prostate Cancer Screening and miRNAs - miRNAs and Resistance to Anti-Cancer Drugs - Theoretical Limitations - Discussion of Patent Issues - Interviews with Industry Experts - Market Estimate As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail: - Agilent Technologies - AMSBIO - Applied Biosystems - DiamiR, LLC - Dicerna - Eisai Biomarkers and Personalized Medicine - Diagnostics - Genomic Health Inc. - Gensignia - GlaxoSmithKline Discovery and Molecular Toxicology - Groove Biopharma (formerly Mirina) - Hologic-Gen Probe Inc. - Illumina, Inc. - Isis Pharmaceuticals - Mello Biotechnology Inc. - Microlin Bio - MiRagen Therapeutics - MiRNA Therapeutics - Novartis - Pacific Edge Biotechnology - Prolias Technologies - Regulus Therapeutics - Rosetta Genomics - Santaris Pharma A/S - Sirnaomics, Inc. - Somagenics - Diagnostics: Small RNA Assays and Biomarker Validation - Tekmira Pharmaceuticals Corporation - Thermadiag - Thermo Fisher Scientific, Inc. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Current State of the Art 4. Companies Developing microRNA Diagnostic Technologies 5. Market Estimates and Forecasts 6. Interviews with Industry Experts: Biomarkers 7. The Future of miRNA-Based Diagnostics For more information visit http://www.researchandmarkets.com/research/fj...a_research
ISIS: 50.39 (+0.68), A: 40.90 (+0.10), TKMR: 16.41 (+0.04), ILMN: 190.42 (+0.57), RGLS: 16.63 (-1.49), GSK: 46.38 (+0.10), HOLX: 26.39 (-0.25), GHDX: 32.50 (-0.04), NVS: 95.75 (+0.17)
Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting
PR Newswire - Tue Nov 18, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Monday, December 8, 2014 at 9:00 a.m. Eastern Time to discuss the ISIS-FXIRx data presented at the 56th American Society of Hematology Annual Meeting and Exposition.
ISIS: 50.39 (+0.68)
Post Earnings Update: Isis Pharmaceuticals Has Climbed 9.8% Higher in Past Week (ISIS)
Comtex SmarTrend(R) - Mon Nov 17, 3:34PM CST
When Isis Pharmaceuticals (NASDAQ:ISIS) reported earnings a week ago on November 7th, 2014, analysts, on average, expected the company to report a loss of $0.20 on sales of $44.2 million. Isis Pharmaceuticals actually reported a loss of $0.23 per share on sales of $44.1 million, missing EPS estimates by $0.04 and matching revenue estimates. Shares of Isis Pharmaceuticals have climbed from $44.59 to $48.98, representing a gain of 9.8% since the company reported earnings 10 days ago.
ISIS: 50.39 (+0.68)
Cure SMA Presents Isis Pharmaceuticals with SMA Breakthrough Award
PR Newswire - Mon Nov 17, 11:04AM CST
On November 15, Isis Pharmaceuticals (NASDAQ: ISIS) was presented with the 2014 SMA Breakthrough Award as part of the Cure SMA Gala of Hope in Seal Beach, CA. The award was accepted by Stanley T Crooke, Ph.D., M.D., who is the founder, chairman, and chief executive officer of Isis Pharmaceuticals.
ISIS: 50.39 (+0.68)
Isis Pharmaceuticals Up 49.0% Since SmarTrend Uptrend Call (ISIS)
Comtex SmarTrend(R) - Mon Nov 17, 9:26AM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 3 months, Isis Pharmaceuticals has returned 48.98% as of today's recent price of $49.35.
ISIS: 50.39 (+0.68)
Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 303.63 (-1.93), ISIS: 50.39 (+0.68), AZN: 75.48 (+1.50), SNY: 48.35 (-0.01)
Isis Pharmaceuticals to Present at Upcoming Investor Conferences
PR Newswire - Fri Nov 14, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at:
ISIS: 50.39 (+0.68)
Cramer's Lightning Round - VeriFone Is Going To Have A Big Year (11/12/14)
SA Editor Miriam Metzinger - Seeking Alpha - Thu Nov 13, 8:05AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday November 12. Bullish Calls: VeriFone (NYSE: PAY ): "I like it. It is integral to Apple Pay. It is going to have a big year." ...
BTU: 10.72 (-0.54), ISIS: 50.39 (+0.68), FRT: 131.53 (-0.60), PAY: 36.74 (-0.25)
'Mad Money' Lightning Round: VeriFone Is Integral to ApplePlay
at The Street - Thu Nov 13, 5:00AM CST
Cramer says Hertz is very cheap but wants to see how their accounting problems play out.
DDR: 17.87 (-0.20), BTU: 10.72 (-0.54), HTZ: 22.18 (-0.50), ISIS: 50.39 (+0.68), ISBC: 10.74 (-0.03), FRT: 131.53 (-0.60), BAC: 17.04 (-0.10), PAY: 36.74 (-0.25)
AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods
PR Newswire - Thu Nov 13, 2:01AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively. The agreement builds on an existing collaboration between AstraZeneca and Isis Pharmaceuticals, a leader in the field of antisense, and supports AstraZeneca's research and development capabilities in the area of antisense oligonucleotide-based therapeutics and RNA biology. Initial project areas will be oncology and cardiovascular and metabolic diseases (CVMD).
ISIS: 50.39 (+0.68)
Jim Cramer's 'Mad Money' Recap: Pining for Quiet Stock That Climbs
at The Street - Wed Nov 12, 7:57PM CST
While the bulls and bears battle it out over high-flying stocks like Alibaba and Twitter, Cramer said he'd rather just own Apple because it doesn't make waves, it makes money.
HTZ: 22.18 (-0.50), PNRA: 168.65 (+0.70), FB: 73.84 (-0.50), TCS: 22.63 (-0.59), BAC: 17.04 (-0.10), FRT: 131.53 (-0.60), YHOO: 51.17 (-0.58), DDR: 17.87 (-0.20), BTU: 10.72 (-0.54), SAVE: 76.09 (-0.24), ISIS: 50.39 (+0.68), CMG: 658.01 (-0.08), AAL: 44.59 (-0.46), ISBC: 10.74 (-0.03), PAY: 36.74 (-0.25), TWTR: 39.62 (-0.99), DOW: 51.48 (-0.59), BABA: 109.77 (-1.04)
Critical Alerts For Twitter, Isis Pharmaceuticals, TrueCar and Myriad Genetics Released By InvestorsObserver
PR Newswire - Wed Nov 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for TWTR, ISIS, TRUE and MYGN.
MYGN: 32.30 (-0.56), ISIS: 50.39 (+0.68), TRUE: 17.74 (+0.32), TWTR: 39.62 (-0.99)
Isis Pharmaceuticals Prices Offering of $425 Million of 1.00% Convertible Senior Notes
PR Newswire - Wed Nov 12, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the pricing of its offering of $425.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes"
in a private placement. Isis also granted the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $75.0 million aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. The sale of the Convertible Notes is expected to close on November 17, 2014, subject to customary closing conditions. ISIS: 50.39 (+0.68)
Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 12, 4:20AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 11. CEO Interview: Bill Tauscher, Blackhawk (NASDAQ: HAWK ). Other stocks mentioned: Safeway (NYSE: SWY ) Blackhawk ( HAWK ) is a leading global...
WFM: 47.85 (-0.04), DHI: 24.67 (+0.04), AMZN: 326.78 (+1.85), TSLA: 248.35 (-9.35), KR: 58.47 (-0.05), SWY: 34.85 (+0.07), CLX: 100.52 (-0.25), XOM: 95.41 (+0.54), FCAU: 12.25 (-0.56), INO: 9.50 (-0.36), WHR: 179.27 (+2.05), T: 35.35 (-0.37), ISIS: 50.39 (+0.68), VALE: 8.56 (+0.03), EOG: 98.46 (+0.79), HAWK: 35.32 (-1.02), SHW: 240.18 (-1.14), VZ: 50.48 (-0.74), TOL: 33.96 (+0.07), REGN: 416.07 (+2.85), KELYA: 15.51 (-0.08), BABA: 109.82 (-0.99)
Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names
at The Street - Tue Nov 11, 7:59PM CST
Cramer says record-low interest rates seem to have finally paid off for the home builders. That means good things for the folks who make interior items, too.
DHI: 24.67 (+0.04), TSLA: 248.35 (-9.35), AMZN: 326.78 (+1.85), CY: 10.47 (+0.12), XOM: 95.41 (+0.54), KEX: 101.47 (+1.22), LRN: 12.14 (-0.29), BWLD: 162.49 (+1.63), ADBE: 70.83 (unch), GTLS: 42.24 (-0.87), TWX: 81.18 (+0.68), WHR: 179.27 (+2.05), T: 35.35 (-0.37), LYB: 88.88 (-0.16), ISIS: 50.39 (+0.68), CMG: 658.01 (-0.08), EOG: 98.46 (+0.79), HAWK: 35.32 (-1.02), SHW: 240.18 (-1.14), VZ: 50.48 (-0.74), DOW: 51.48 (-0.59), REGN: 416.07 (+2.85), KELYA: 15.51 (-0.08), CBS: 52.71 (+0.17)
Isis Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 8.81%
Comtex SmarTrend(R) - Tue Nov 11, 3:42PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $48.10 to a high of $52.24. Yesterday, the shares gained 8.8%, which took the trading range above the 3-day high of $47.25 on volume of 10.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ISIS: 50.39 (+0.68)
(0)
(0)Ionis Pharmaceuticals, Inc. (IONS) Stock Research Links
Scroll down for more posts ▼